JP Morgan Chase
IMRX icon

JP Morgan Chase’s Immuneering IMRX Stock Holding History

JP Morgan Chase’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Buy
32,520
+26,101
+407% +$132K ﹤0.01% 5724
2026
Q1 		$31.3K Sell
6,419
-346
-5% -$1.77K ﹤0.01% 6375
2025
Q4 		$44.5K Buy
6,765
+5,265
+351% +$33.8K ﹤0.01% 6278
2025
Q3 		$10.5K Sell
1,500
-474
-24% -$2.46K ﹤0.01% 6629
2025
Q2 		$6.65K Hold
1,974
– – ﹤0.01% 6379
2025
Q1 		$3K Hold
1,974
– – ﹤0.01% 6498
2024
Q4 		$4.34K Sell
1,974
-450
-19% -$933 ﹤0.01% 6537
2024
Q3 		$6.04K Buy
2,424
+450
+23% +$654 ﹤0.01% 6455
2024
Q2 		$2.53K Sell
1,974
-7,315
-79% -$12K ﹤0.01% 6497
2024
Q1 		$26.8K Sell
9,289
-6,785
-42% -$38K ﹤0.01% 6147
2023
Q4 		$118K Sell
16,074
-4,285
-21% -$28.5K ﹤0.01% 5654
2023
Q3 		$156K Buy
20,359
+3,577
+21% +$32.9K ﹤0.01% 5216
2023
Q2 		$170K Buy
16,782
+15,752
+1,529% +$151K ﹤0.01% 5172
2023
Q1 		$10K Buy
1,030
+70
+7% +$397 ﹤0.01% 6118
2022
Q4 		$5K Sell
960
-183
-16% -$1.62K ﹤0.01% 6159
2022
Q3 		$16K Buy
1,143
+10
+0.9% +$79 ﹤0.01% 5861
2022
Q2 		$6K Sell
1,133
-10,836
-91% -$57.8K ﹤0.01% 6122
2022
Q1 		$78K Buy
11,969
+6,515
+119% +$62.6K ﹤0.01% 5613
2021
Q4 		$88K Buy
5,454
+2,287
+72% +$55.7K ﹤0.01% 5739
2021
Q3 		$84K Buy
+3,167
New +$85.1K ﹤0.01% 5653

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

JP Morgan Chase's IMRX Position: Q2 2026 in Review

JP Morgan Chase increased its Immuneering (IMRX) stake by 407% in Q2 2026, buying an estimated $132K and bringing the position to 32,520 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #5724.

JP Morgan Chase first reported a position in IMRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $170K in Q2 2023. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • JP Morgan Chase held 32,520 shares of Immuneering worth $164K as of Q2 2026.
  • JP Morgan Chase bought 26,101 Immuneering shares in Q2 2026, an estimated $132K.
  • Immuneering made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5724 holding.
  • JP Morgan Chase first reported a position in Immuneering in Q3 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Immuneering position peaked at $170K in Q2 2023.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.